FRANCISCO S. TATAD
FRANCISCO S. TATAD

THE government decision to use Dengvaxia, the French-made anti-dengue vaccine, on Filipino grade-four schoolchildren without adequate precautionary measures, has become a scandal of monumental proportions after its manufacturer Sanofi-Pasteur recently revealed that it could cause severe, even fatal, infection on those who have not been infected before vaccination. Some 830,000 schoolchildren have reportedly been vaccinated under the anti-dengue immunization program; from January to September 2017, the Department of Health was reported to have recorded 97,287 dengue cases nationwide.

Premium + Digital Edition

Ad-free access


P 80 per month
(billed annually at P 960)
  • Unlimited ad-free access to website articles
  • Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)

TRY FREE FOR 14 DAYS
See details
See details